Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey M Conroy

Showing results (21-30 of 67) with videos related to

Pageof 7
Sort By:
Iscience|April 18, 2024
High indoleamine 2,3-dioxygenase transcript levels predict better outcome after front-line cancer immunotherapyYu Fujiwara, Shumei Kato, Daisuke Nishizaki, et al.
Molecular Cancer Therapeutics|August 24, 2023
Cancer-Immunity Marker RNA Expression Levels across Gynecologic Cancers: Implications for ImmunotherapyJessica Jou, Shumei Kato, Hirotaka Miyashita, et al.
American Journal of Cancer Research|June 11, 2024
TIM-3 transcriptomic landscape with clinical and immunomic correlates in cancerJibran Ahmed, Daisuke Nishizaki, Hirotaka Miyashita, et al.
Molecular Cancer Therapeutics|May 25, 2026
GITR and GITR-L RNA Expression Levels Correlate with Better Survival and Response to ImmunotherapyPeter Moussa, Razelle Kurzrock, Daisuke Nishizaki, et al.
Molecular Cancer Therapeutics|May 5, 2026
GITR and GITR-L RNA Expression Levels Correlate with Better Survival and Response to ImmunotherapyPeter Moussa, Razelle Kurzrock, Daisuke Nishizaki, et al.
Annals of Translational Medicine|February 11, 2021
Immune profiling and immunotherapeutic targets in pancreatic cancerFelicia L Lenzo, Shumei Kato, Sarabjot Pabla, et al.
Cancer Medicine|May 3, 2023
LAG-3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeuticsJacob J Adashek, Shumei Kato, Daisuke Nishizaki, et al.
BMC Genomics|December 12, 2012
OSAT: a tool for sample-to-batch allocations in genomics experimentsLi Yan, Changxing Ma, Dan Wang, et al.
Cancer Communications (London, England)|August 4, 2024
4-1BB transcriptomic expression patterns across malignancies: Implications for clinical trials of 4-1BB agonistsYuji Uehara, Shumei Kato, Daisuke Nishizaki, et al.
Cancer Medicine|December 22, 2023
Pan-cancer analysis of TIM-3 transcriptomic expression reveals high levels in pancreatic cancer and interpatient heterogeneityJungah Lim, Razelle Kurzrock, Daisuke Nishizaki, et al.
Pageof 7

Showing results (21-30 of 67) with videos related to

Sort By:
Pageof 7
Iscience|April 18, 2024
High indoleamine 2,3-dioxygenase transcript levels predict better outcome after front-line cancer immunotherapyYu Fujiwara, Shumei Kato, Daisuke Nishizaki, et al.
Molecular Cancer Therapeutics|August 24, 2023
Cancer-Immunity Marker RNA Expression Levels across Gynecologic Cancers: Implications for ImmunotherapyJessica Jou, Shumei Kato, Hirotaka Miyashita, et al.
American Journal of Cancer Research|June 11, 2024
TIM-3 transcriptomic landscape with clinical and immunomic correlates in cancerJibran Ahmed, Daisuke Nishizaki, Hirotaka Miyashita, et al.
Molecular Cancer Therapeutics|May 25, 2026
GITR and GITR-L RNA Expression Levels Correlate with Better Survival and Response to ImmunotherapyPeter Moussa, Razelle Kurzrock, Daisuke Nishizaki, et al.
Molecular Cancer Therapeutics|May 5, 2026
GITR and GITR-L RNA Expression Levels Correlate with Better Survival and Response to ImmunotherapyPeter Moussa, Razelle Kurzrock, Daisuke Nishizaki, et al.
Annals of Translational Medicine|February 11, 2021
Immune profiling and immunotherapeutic targets in pancreatic cancerFelicia L Lenzo, Shumei Kato, Sarabjot Pabla, et al.
Cancer Medicine|May 3, 2023
LAG-3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeuticsJacob J Adashek, Shumei Kato, Daisuke Nishizaki, et al.
BMC Genomics|December 12, 2012
OSAT: a tool for sample-to-batch allocations in genomics experimentsLi Yan, Changxing Ma, Dan Wang, et al.
Cancer Communications (London, England)|August 4, 2024
4-1BB transcriptomic expression patterns across malignancies: Implications for clinical trials of 4-1BB agonistsYuji Uehara, Shumei Kato, Daisuke Nishizaki, et al.
Cancer Medicine|December 22, 2023
Pan-cancer analysis of TIM-3 transcriptomic expression reveals high levels in pancreatic cancer and interpatient heterogeneityJungah Lim, Razelle Kurzrock, Daisuke Nishizaki, et al.
Pageof 7